Eli Lilly Gets FDA OK of Mounjaro to Cut Cardiovascular Risk in Type 2 Diabetes

By Colin Kellaher

 

Eli Lilly has won U.S. Food and Drug Administration approval for the use of its blockbuster diabetes and weight-loss drug Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes.

Eli Lilly on Friday said the expanded approval covers the use of Mounjaro to lower the risk of major adverse cardiovascular events, including death or non-fatal heart attacks or strokes in adults with type 2 diabetes who are at high risk for those events.

Mounjaro was already approved as an adjunct to diet and exercise to improve blood sugar in people 10 and older with type 2 diabetes.

The Indianapolis drugmaker said it is estimated that as many as one in three adults in the U.S. with type 2 diabetes have undetected cardiovascular disease.

Sales of Mounjaro topped $18.6 billion in the first half of 2026.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 28, 2026 07:39 ET (11:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center